Published Date: 26 Apr 2023
The dreaded hay fever signs, including itchy eyes, sneezing, and a stuffy nose, have arrived for many people with the arrival of spring. Up to 42% of people experience hay fever, making it a widespread condition. Immune system overreaction is the cause of it.
Read Full NewsA new Lancet Oncology Commission highlights a growing "human crisis" in cancer care. Despite advances in treatment and increased survival rates, many patients worldwide are not receiving the compassionate, holistic support ...
Glioblastoma is one of the most aggressive and complex brain cancers. It grows quickly, resists standard treatments, and often leaves patients and their families searching for every possible option.
A European study has demonstrated a sustained long-term reduction in prostate cancer mortality through prostate-specific antigen (PSA) screening. However, the findings also highlight the issue of overdiagnosis, or the detection ...
1.
The Predictive Power of Liquid Biopsy in Colon Cancer Outcomes Is Inconsistent.
2.
Gene therapy for glioblastoma is effectively created by researchers.
3.
When performed by skilled surgeons, robotic surgery for pancreatic tumors is safe and feasible.
4.
Mapping lifelong chronic health risks for childhood cancer survivors
5.
Recent Rise in Early-Onset Solid Tumors Is Associated with Accelerated Aging.
1.
The Genetics of Bernard Soulier Syndrome: What We Know so Far
2.
The Architect's Dilemma: Remodeling the Tumor Microenvironment for a New Era of Cancer Immunotherapy
3.
HCC Codes in Oncology: Care Optimization in Plexiform Neurofibroma Management
4.
From Birthmarks to Tumors: The Science Behind Infantile Hemangioma
5.
Understanding the Causes and Symptoms of Cavernous Sinus Thrombosis
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Oropharyngeal Cancer in Relation to HPV Status
2.
Incidence of Lung Cancer- An Overview to Understand ALK Rearranged NSCLC
3.
Navigating the Complexities of Ph Negative ALL - Part VIII
4.
Guideline Recommendations of Lorlatinib as First-Line Treatment for ALK+ NSCLC
5.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part V
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation